Final Results 2025

hVIVO plc (AIM:HVO) has released its Final Results for 2025, reporting a significant decrease in revenue to £46.8 million, down from £62.7 million in 2024. This decline is accompanied by a sharp drop in adjusted EBITDA to £1.4 million from £16.4 million, resulting in a basic adjusted earnings per share of (0.41)p compared to 1.69p in the previous year. The company's cash reserves have also diminished, falling to £14.3 million from £44.2 million, while the contracted order book decreased to £30 million from a restated £43.5 million. These results reflect the challenges faced during the year, including strategic acquisitions and a difficult market environment. However, hVIVO anticipates high single-digit revenue growth in 2026, suggesting a potential recovery.

When comparing these results to prior disclosures, it is evident that hVIVO's performance has not met expectations. The revenue drop is stark, particularly given that the company had previously indicated a more optimistic outlook. In its half-year results, hVIVO reported revenues of £24.2 million and cash of £23.3 million, which suggested a more stable trajectory. The current results indicate a significant downturn, raising concerns about the company's operational execution and market conditions. Additionally, the adjusted EBITDA margin has plummeted from 26.2% to 3.0%, highlighting the operational challenges that have impacted profitability.

The company's cash position is a critical factor in evaluating its ability to sustain operations and fund future growth. With cash reserves now at £14.3 million, down from £44.2 million, hVIVO faces a tighter financial situation. This reduction in cash could limit the company's ability to invest in growth initiatives or navigate any further market challenges. The contracted order book's decline to £30 million also raises questions about future revenue streams. While the company has indicated a strong pipeline of opportunities and expects growth in 2026, the current cash position suggests that hVIVO may need to secure additional funding to support its operations and strategic initiatives.

In terms of valuation, hVIVO's market capitalisation stands at approximately £59.9 million. When compared to peers in the clinical development sector, such as Synlogic Inc (NASDAQ:SYBX) and Medpace Holdings Inc (NASDAQ:MEDP), which have market caps of around £200 million and £1.5 billion respectively, hVIVO appears undervalued. Synlogic, for instance, has a more diversified product pipeline and a stronger financial position, which may provide it with a competitive edge. Furthermore, Medpace's robust revenue growth and established market presence contrast sharply with hVIVO's recent performance, suggesting that investors may find better value in these alternatives.

The operational highlights from hVIVO's announcement indicate some positive developments, including the completion of strategic acquisitions that aim to enhance the company's capabilities. The acquisition of two Clinical Research Units from CRS for €10 million is expected to diversify hVIVO's therapeutic expertise and expand its service offerings. Additionally, the integration of these units has been completed on schedule, with the business generating cash in Q4 2025. However, the overall financial performance raises concerns about whether these acquisitions will translate into the anticipated growth and profitability in the near term.

A specific red flag in this announcement is the significant decline in both revenue and adjusted EBITDA, which suggests that the company is struggling to adapt to the current market environment. The drop in the contracted order book further underscores this challenge, as it indicates a potential slowdown in client demand for hVIVO's services. While the company has highlighted its strong pipeline of opportunities and expects growth in 2026, the current financial metrics do not provide a solid foundation for this optimism.

Looking ahead, hVIVO has indicated that it is in active discussions with ILiAD Biotechnologies regarding a human challenge trial and is finalising the agreement. This could serve as a potential catalyst for future revenue growth, but the timing and outcome of these discussions remain uncertain. The company also anticipates high single-digit revenue growth in 2026, weighted towards the second half of the year. However, given the current financial position and market conditions, investors may remain cautious about the feasibility of these projections.

In conclusion, hVIVO's Final Results for 2025 present a mixed picture. While the company has made strategic acquisitions and established a diversified service offering, the significant decline in revenue and profitability raises concerns about its operational execution and market adaptability. The anticipated growth in 2026 may provide some optimism, but the current financial metrics suggest that hVIVO faces considerable challenges ahead. This announcement can be classified as moderate, as it reflects a transitional year with potential for recovery, but the headline sentiment is tempered by the reality of the company's financial performance and market conditions.

Key insights

• ●Revenue fell to £46.8M from £62.7M, raising concerns about growth.
• ●Cash reserves decreased to £14.3M, limiting operational flexibility.
• ●Contracted order book down to £30M, indicating potential demand challenges.

Disagree with this article?